

## ASX Announcement

### Imugene appoints Dr Giovanni Selvaggi as CMO

---

**Sydney, Australia, 04 October 2022:** Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, is pleased to announce the appointment of Dr Giovanni Selvaggi as Chief Medical Officer (CMO).

Dr Selvaggi is a pulmonologist, trained in thoracic malignancies management with a focus on lung cancers and mesothelioma. He brings more than a decade of experience in the pharmaceutical industry which has seen him in clinical development focused roles of increasing responsibility with GlaxoSmithKline (GSK), Novartis Oncology and Bristol Myers Squibb.

Dr Selvaggi held a pivotal role in Novartis successful development and approval of ceritinib (or Zykadia, targeting non-small cell lung cancer/NSCLC) and was part of the immunotherapy team at Bristol Myers Squibb that led to the approval of nivolumab (Opdivo) in third line small cell lung cancer.

His most recent role with US oncology company Xcovery Holdings Inc saw Dr Selvaggi progress from CMO to be appointed CEO and CMO early in 2021. Prior to this Dr Selvaggi also served as Vice President, Clinical Development at Oncolytics Biotech in Canada. Additionally, he has been a well-regarded presenter at major international medical conferences as well as having authored numerous peer reviewed articles in major oncology journals.

Prior to entering the pharmaceutical sector Dr Selvaggi was as an attending physician at Thoracic Oncology - San Luigi Hospital in Turin, Italy. This included being an investigator on various oncology clinical trials.

Dr Selvaggi studied at the Medical School at the University of Torino in Italy, where he also completed his Residency in Respiratory Medicine at the Postgraduate Medical School.

Imugene's M.D. & CEO, Ms Leslie Chong said: "We are delighted to welcome Dr Selvaggi to the Imugene team as our clinical development activities grow in both number and importance. He brings big pharma prowess that we expect to be very valuable, as well as having an excellent understanding of the experience of the institutions and investigators typically associated with drug development. He's another excellent appointment to the world-class team we're building."



For more information please contact:

**Leslie Chong**

**Managing Director and Chief Executive Officer**

info@imugene.com

**Investor Enquiries**

investor@imugene.com

**Media Enquiries**

Matt Wright

matt@nwrcommunications.com.au

Follow us on Twitter @TeamImugene

Like us on Facebook @Imugene

Connect with us on LinkedIn @Imugene Limited

View us on YouTube @Imugene Limited

**About Imugene (ASX:IMU)**

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T's for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene's immuno-oncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.



*Release authorised by the Managing Director and Chief Executive Officer  
Imugene Limited, Level 3, 62 Lygon Street, Carlton, VIC, 3053, Australia*